Inclisiran approved in the EU for the treatment of adults with hypercholesterolemia or mixed dyslipidaemia

Inclisiran is a small-interfering RNA which targets hepatic PCSK9 synthesis and increases recycling of the LDL-C receptor and its expression on the hepatocyte cell surface, thereby increasing LDL-C uptake and lowering LDL-C levels in the circulation.

Source:

Reuters Health